Pacira BioSciences
PCRX
280 hedge funds and large institutions have $1.48B invested in Pacira BioSciences in 2024 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 105 increasing their positions, 76 reducing their positions, and 39 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 105 | Existing positions reduced: 76
31% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 39
5.69% more ownership
Funds ownership: 105.79% → 111.48% (+5.7%)
4% more funds holding
Funds holding: 270 → 280 (+10)
3% more capital invested
Capital invested by funds: $1.44B → $1.48B (+$46.8M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
70% less call options, than puts
Call options by funds: $12.3M | Put options by funds: $40.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
+$16.8M |
| 2 |
JP Morgan Chase
New York
|
+$14.7M |
| 3 |
FWIA
Fort Washington Investment Advisors
Cincinnati,
Ohio
|
+$13.2M |
| 4 |
DPCM
Doma Perpetual Capital Management
Miami,
Florida
|
+$11.9M |
| 5 |
Barclays
London,
United Kingdom
|
+$10.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ClearBridge Investments
New York
|
-$34.3M |
| 2 |
ACM
Archon Capital Management
Seattle,
Washington
|
-$15.7M |
| 3 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$7.7M |
| 4 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
-$5.54M |
| 5 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$5.32M |
PCRX Hedge Fund Activity: Q2 2024 in Review
280 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Pacira BioSciences (PCRX) for Q2 2024, worth a combined $1.48B — up 3.3% from $1.44B a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new PCRX positions and 39 closed out — a net gain of 12 holders — while 105 added to existing stakes and 76 trimmed.
The largest buyer was Pacer Advisors, adding an estimated $16.8M. The largest seller was ClearBridge Investments, exiting entirely with an estimated $34.3M sold.
- 280 institutional investors held Pacira BioSciences (PCRX) as of Q2 2024, up from 270 in Q1 2024.
- Funds reported $1.48B of Pacira BioSciences stock for Q2 2024, up 3.3% quarter-over-quarter.
- 51 funds opened new Pacira BioSciences positions in Q2 2024 and 39 closed out, a net change of +12 holders.
- The largest Pacira BioSciences buyer in Q2 2024 was Pacer Advisors, an estimated $16.8M added.
- The largest Pacira BioSciences seller in Q2 2024 was ClearBridge Investments, an estimated $34.3M sold.
Based on aggregated 13F filings for Q2 2024.